Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: PR Newswire
PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France."We continue to be pleased with the promising efficacy and safety data of KSI-301," said Victor Perlroth, M.D., Kodiak's Chief Executive Officer. "At EURETINA, we will report on outcomes with over 100 patients dosed and a growing safety database with over 250 injections of KSI-301. The data being presented continue to demonstrate the potential for KSI-301 to be a first-line intravitreal anti-VEGF therapy."Details of the presentations are below.EURETINA 2019 CongressOral Presentation: Novel anti-VEGF antibody biopolymer conjugate KSI-301 with potential for extended durability in retinal vascular diseases: first-time results from a phase 1
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsPR Newswire
- Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy [Yahoo! Finance]Yahoo! Finance
KOD
Earnings
- 5/15/24 - Beat
KOD
Sec Filings
- 5/15/24 - Form 10-Q
- 5/15/24 - Form 8-K
- 4/23/24 - Form ARS
- KOD's page on the SEC website